Medulloblastoma (MB) is recognized as the most prevalent malignant brain tumor in pediatric patients, comprising approximately 25–30% of all childhood brain tumors. At Alfa Cytology, we are committed to pioneering new therapeutic approaches for medulloblastoma treatment for our clients.
Introduction to Medulloblastoma
Medulloblastoma originates in the cerebellum, specifically in the posterior fossa. The World Health Organization (WHO) classifies MB into four distinct molecular subtypes: WNT, Sonic Hedgehog (SHH), Group 3, and Group 4. Each subtype exhibits unique biological behaviors, prognostic outcomes, and therapeutic responses, making personalized treatment approaches essential.
Fig.1 Molecular features, prognosis, and location of the medulloblastoma subtypes. (Lombardi, G., et al., 2022)
Recent advancements in molecular biology have illuminated the pathogenesis of these subtypes. For instance, WNT medulloblastomas typically feature mutations in the CTNNB1 gene, which encodes β-catenin, leading to the activation of WNT signaling pathways. In contrast, SHH medulloblastomas are associated with alterations in the PTCH1 and SUFU genes, highlighting the role of the Hedgehog signaling pathway in tumor development. Understanding these molecular underpinnings is crucial for developing targeted therapies that can improve clinical outcomes for affected children.
Therapeutic Development for Medulloblastoma
The therapeutic landscape for medulloblastoma has evolved significantly over the past decade. Traditional treatment modalities include surgical resection, radiotherapy, and chemotherapy. However, the advent of molecular profiling has paved the way for innovative therapeutic strategies tailored to the specific subtype of medulloblastoma.
|
NCT |
Target |
Therapeutics |
Phase |
| NCT04315064 |
Pan Histone Deacetylase (HDAC) Inhibitor |
MTX110 |
|
| NCT04696029 |
Ornithine Decarboxylase Inhibitor |
Difluoromethylornithine (DFMO) |
|
| NCT01708174 |
Selective Smoothened Inhibitor |
LDE225 |
|
| NCT03904862 |
Selective Inhibitor of CK2 (Casein Kinase 2) |
CX-4945 |
|
| NCT01483820 |
Microtubule Inhibitor |
TPI 287 |
|
| NCT01326104 |
Autologous Tumor-Specific T Cell Immunotherapy (TTRNA-xALT) |
Biological: TTRNA-xALT |
|
| NCT06161519 |
Topoisomerase I Inhibitor |
PLX038 |
|
Our Services
At Alfa Cytology, we are dedicated to advancing research and development in the field of medulloblastoma through our comprehensive preclinical services. Our expertise spans molecular profiling, in vivo and in vitro studies, biomarker discovery, and strategic consultation.
Case Study - Medulloblastoma Allograft Model
Model Introduction
The medulloblastoma allograft model provides a clinically relevant preclinical platform for evaluating novel gene therapy approaches for this aggressive pediatric brain tumor. Medulloblastoma is the most common malignant brain tumor in children, with current treatments including surgery, chemotherapy, and craniospinal irradiation that cause devastating long-term side effects. This model, established using tumor cells derived from Patched1 heterozygous mice that spontaneously develop Sonic Hedgehog-type medulloblastoma, recapitulates key molecular features of human disease.
Model Information
- Model: Medulloblastoma Allograft Model
- Animal: Nude Mice
- Weight: 20-22 g
Model Construction
The medulloblastoma allograft model was established by subcutaneous injection of 1.5 × 104 cells/μL primary tumor cells into the dorsal flank region of athymic nude mice. When tumors reached approximately 100-150 mm3, mice were randomly assigned to treatment groups. Tumor volume was monitored by caliper measurement throughout the study.
Fig. 2 Workflow of medulloblastoma allograft model establishment and gene therapy treatment regimen. (Source: Alfa Cytology)
In Vivo Efficacy Evaluation
This study employed the established medulloblastoma allograft model to evaluate the therapeutic efficacy of AAV-mediated gene delivery and its effects on tumor growth.
- AAV-Mediated Gene Therapy Inhibits Tumor Growth: Treatment with AAV-mediated gene therapy significantly inhibited tumor growth during the injection period. Tumor volumes were significantly smaller in treated mice compared to controls at the end of treatment.
- Reduced Tumor Cell Proliferation: Gene therapy treatment significantly decreased tumor cell proliferation, as evidenced by reduced Ki67 positivity and diminished BrdU incorporation in treated tumors compared to controls.
Fig. 3 Anti-tumor activity of AAV-mediated gene therapy in the medulloblastoma allograft model. Data are presented as mean ± SEM. (Source: Alfa Cytology)
Contact Us
For more information about our services or to discuss potential collaborations, please
contact us at Alfa Cytology. Our team is committed to driving innovation and improving treatment options for medulloblastoma.
Reference
- Fang, F.Y.; Rosenblum, J.S.; Ho, W.S.; Heiss, J.D. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. Cancers 2022, 14, 2285. Lombardi, G.; et al. (2022). Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview[J]. Cancers. 14, 3646.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
